NC: Behavior Change Strategies (2007-2008)
Citation:
Study Design:
Class:
- Click here for explanation of classification scheme.
Quality Rating:
Research Purpose:
- To compare two different extended treat interventions (relapse prevention therapy and problem solving) with standard behavior therapy
- To determine whether there was a relative advantage of intensive didactic training in a comprehensive range of relapse prevention skills, compared with continued professional assistance in the form of therapist-led group problem-solving.
Inclusion Criteria:
- Age: 21 to 60 years
- BMI: 27 to 40
- Good health
- Physician's approval to participate in a diet and exercise weight-loss intervention.
Exclusion Criteria:
None specified.
Description of Study Protocol:
- Recruitment: Participants recruited from newspaper advertisements and screened for eligibility.
- Design: Randomized controlled trial.
Intervention
- All participants received the same initial cognitve-behavioral weight-loss intervention
- Weekly two-hour group sessions with 11 to 14 members per group, for 20 weeks
- Three groups:
- Behavior Therapy (BT): Two groups
- Relapse Prevention Therapy (RPT): Three groups
- Problem-Solving Therapy (PST): Three groups.
- Standard behavioral weight-management techniques taught in a didactic fasion: Self-monitoring, goal-setting, stimuls control, etc.
- Instructed to follow 1,200kcal (1,200 per day for women), low-fat diet (25% of total kcal per day)
- Home-based walking program of 30 minutes per day, five days per week
- Conducted by pairs of clinical psychology graduate students, who adhered to a written protocol.
- During year after initial treatment
- Behavior Therapy
- Relapse Prevention Therapy
- Problem-Solving Therapy.
Statistical Analysis
- Analysis of variance (ANOVA) for comparisons of groups
- Multi-variate ANOVA (MANOVA) for comparisons of multiple variable between groups
- Chi-square.
Data Collection Summary:
Timing of Measurements
- Weight, eating and exercise diaries: Weekly for 20 weeks
- BT: Weight; six and 12 months
- RPT and PST: Weight, eating and exercise diaries; bi-weekly for one year.
Dependent Variables
- Body weight: Scale (type and calibration not specified)
- Adherence: Self-reported for nine behavioral weight-management strategies (Likert scale; 1=non-adherence and 7=full adherence).
Independent Variables
BT, RPT or PST.
Description of Actual Data Sample:
Initial N
103 (gender not specified).
Attrition (Final N)
- Completion of initial behavioral treatment
- N=88; 80 females and eight males, 85%
- 80 females included in analysis, eight males excluded because they were unequally distributed between groups.
- Completion of extended therapy (dropouts were those who withdrew voluntarily or attended fewer than two sessions during Months 12 to 17)
- RPT: 29%
- PST: 34%.
- Final assessment (weight)
- BT: 83%
- RPT: 71%
- PST: 66%.
Age
Final sample: Mean (SD)
- BT (N=18): 45.23 (10.08) years
- RPT (N=28): 49.17 (7.21) years
- PST (N=34): 45.36 (9.33) years.
Ethnicity
Not specified.
Other Relevant Demographics
Education
- BT: 13.13 (1.93) years
- RPT: 14.00 (1.63) years
- PST: 14.50 (2.06) years.
Anthropometrics
- Height (m)
- BT: 1.62 (0.06)
- RPT: 1.66 (0.06)
- PST: 1.65 (0.06).
- Weight (kg)
- BT: 94.67 (11.35)
- RPT: 96.95 (13.69)
- PST: 97.96 (16.01).
- Body mass index (BMI; kg/m2)
- BT: 36.37 (4.70)
- RPT: 35.00 (3.96)
- PST: 36.10 (4.93).
Location
United States.
Summary of Results:
- Completers (N=58) vs. non-completers (i.e., dropped out or did not complete final assessment; N=22)
- Attendance during initial treatment was equivalent
- Completers: 86%
- Non-completers: 93%
- P=0.502.
- Attendance during extended treatment was poorer for non-completers
- Completers: 73%
- Non-completers: 33%
- P=0.0001.
- Non-completers had higher initial body weights than completers: 103.2kg vs. 94.4kg; P=0.012
- Non-completers had non-significatly smaller reductions in percentage of body weight during initial treatment than completers: 10% vs. 8%; P=0.163.
Mean Net Weight (kg) Changes [Mean (SD)] by Conditions Over Time for Completers
Time Period | BT (N=15) | RPT (N=20) | PST (N=23) |
Baseline to Month 5 |
-9.54 (4.94)
|
-8.41 (4.55)
|
-9.28 (5.21)
|
Month 5 to Month 11 |
2.92 (4.76)
|
-0.97 (3.89)
|
-2.05 (3.75)
|
Month 11 to Month 17 |
2.47 (3.91)
|
3.53 (2.96)
|
0.54 (3.14
|
Baseline to Month 17 |
-4.14 (4.86)
|
-5.85 (6.39)
|
-10.82 (8.65)
|
Classification of Participants According to Categories of Change in Body Weight (Percentage) From Baseline to Final Follow-Up
Category of Change | BT | RPT | PST | |||
N |
% |
N |
% | N | % | |
Lost 10.0% or greater |
1
|
5.6
|
6
|
21.4
|
12
|
35.3
|
Lost 5.0% to 9.9% |
6
|
33.3
|
6
|
21.4
|
6
|
17.6
|
Lost 0.0% to 4.9% |
9
|
50.0
|
12
|
42.9
|
13
|
38.2
|
Gained weight |
2
|
11.1
|
4
|
14.3
|
3
|
8.8 |
- A larger percentage of PST participants achieved a clinically significant loss of more than 10% body weight than did BT participants (P=0.025)
- Differences between the RPT and BT and between PST and RPT were not significant.
Mean (SD) Adherence Scores for Completers by Condition at Months Five, 11 and 17
Assessment Point | BT (N=15) | RPT (N=20) | PST (N=23) |
Month 5 |
53.8 (7.61)
|
48.7 (4.81)
|
52.48 (8.01)
|
Month 11 |
36.20 (13.91)
|
42.25 (11.41)
|
45.78 (9.53)
|
Month 17 |
29.07 (10.14)
|
34.00 (13.39)
|
38.74 (10.35)
|
- PST group demonstrated significantly better adherence to behavioral weight management strategies than the BT group from Months Five to 11 (P=0.043) and from Months 11 to 17 (P=0.041).
Other Findings
- The effect of treatment condition on weight loss was significant (P=0.01)
- When analyzed with adherence entered, the results showed a significant effect for conditions (P=0.059). Amount of variance accoudnted for by adherence: R2=0.72.
Author Conclusion:
- An extended treatment intervention based on a problem-solving model of obesity management demonstrated significantly better weight reduction and long-term maintenance of lost weight than standard BT
- Extended professional contact alone may not be sufficient to improve long-term weight management.
Funding Source:
Government: | Dept. of Veterans Affairs |
Reviewer Comments:
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | Yes | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
2.2. | Were criteria applied equally to all study groups? | Yes | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | ??? | |
3. | Were study groups comparable? | Yes | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | Yes | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | Yes | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | Yes | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | N/A | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | N/A | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
4. | Was method of handling withdrawals described? | Yes | |
4.1. | Were follow-up methods described and the same for all groups? | Yes | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | Yes | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | Yes | |
4.4. | Were reasons for withdrawals similar across groups? | ??? | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | ??? | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | ??? | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | ??? | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | Yes | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | N/A | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | Yes | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | Yes | |
6.6. | Were extra or unplanned treatments described? | N/A | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | Yes | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | N/A | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | Yes | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | N/A | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | Yes | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |